

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

**POLL RESULTS FOR
THE EXTRAORDINARY GENERAL MEETING AND THE
SECOND EXTRAORDINARY GENERAL MEETING
HELD ON 3 DECEMBER 2020**

SUMMARY

The extraordinary general meeting (the “EGM”) and the second extraordinary general meeting (the “Second EGM”) of Shandong Weigao Group Medical Polymer Company Limited (the “Company”) were held on 3 December 2020. The Board of the Company (the “Board”) is pleased to announce that resolutions as set out in the notices of the EGM and the Second EGM were duly passed by way of poll.

* For identification purpose only

POLL RESULT OF THE SGM

Reference is made to the notice of the extraordinary general meeting (“Notice of the EGM”) of the Company dated 16 November 2020. Terms used in this announcement shall have the same meanings as stated in the circulars of the Company and Notice of the EGM dated 16 November 2020 unless the context requires otherwise. The resolution as set out in the Notice of the EGM were passed by polled. The poll result of the resolutions is stated as follows:

ORDINARY RESOLUTION	No of votes (%)		Total number of votes present and voting
	FOR	AGAINST	
1. “ THAT the Purchase Framework Agreement (as amended by the Supplemental Purchase Framework Agreement), a copy of which is produced at the meeting and marked “A” and initialed by the chairman of the meeting for the purpose of identification, and the transactions contemplated thereby (including the annual caps) be and is hereby approved and confirmed and any one director of the Company be and is hereby authorised to do all such acts or things and sign all documents deemed necessary by him/her for the purpose of giving effect to the Purchase Framework Agreement (as amended by the Supplemental Purchase Framework Agreement) and the transactions contemplated thereunder.”	1,137,680,928 100%	0 0%	1,137,680,928 100%

The holding of the EGM was in compliance with the requirements of the Company Law of the PRC and the Articles of Association of the Company. The EGM was chaired by Mr. Zhang Hua Wei, the chairman of the Company. As more than half of the votes were casted in favour of the ordinary resolution numbered (1) in the EGM, the resolution was duly passed by way of poll as ordinary resolution of the Company.

As at the date of the EGM, the total number of issue shares (“Shares”) of the Company entitling the Shareholders to attend and vote for or against the resolutions at the EGM was 4,522,332,324 H Shares. There were no Shares entitling the holders to attend and vote only against the resolution proposed at the EGM. Trustee who administers share award scheme of the Company did not exercise the voting rights attached to any of 23,564,000 H Shares under the share award scheme. Weigao Holding (being a controlling Shareholder of the Company), Zhang Hua Wei, Zhou Shu Hua and Wang Yi (being directors of Weigao Holding Group), who hold a total of 2,165,847,676 H Shares of the Company, were abstained from voting.

POLL RESULT OF THE SECOND EGM

Reference is made to the notice of the second extraordinary general meeting (“Notice of the Second EGM”) of the Company dated 16 November 2020. Terms used in this announcement shall have the same meanings as stated in the circular of the Company and Notice of the Second EGM dated 16 November 2020 unless the context requires otherwise. The resolution as set out in the Notice of the Second EGM was passed by polled. The poll result of the resolution is stated as follows:

SPECIAL RESOLUTION	No of votes (%)		Total number of votes present and voting
	FOR	AGAINST	
1. “THAT: (i) the mandate for the issuance of the Debt Securities (as defined in the circular (the “Circular”) of the Company dated 16 November 2020) on the terms set out in the Circular (a copy of which marked “A” and signed by the chairman of the meeting for the purpose of identification is produced to the meeting) (the “Mandate”) be and is hereby approved and confirmed;	2,663,733,433 82.28%	573,642,203 17.72%	3,237,375,636 100%

SPECIAL RESOLUTION	No of votes (%)		Total number of votes present and voting
	FOR	AGAINST	
<p>(ii) the board of the Company be and is hereby authorised to determine, in its absolute discretion, all matters relating to the issuance of the Debt Securities under the Mandate including but not limited to:</p> <p>(1) determining the type of the Debt Securities to be issued;</p> <p>(2) determining the use of proceeds from the issue of the Debt Securities according to the actual needs of the Group (as defined in the Circular);</p> <p>(3) determining the terms and conditions of Debt Securities;</p>			

SPECIAL RESOLUTION	No of votes (%)		Total number of votes present and voting
	FOR	AGAINST	
<p>(4) appointing the relevant professional parties to advise and assist the Company in the issuances of the Debt Securities including liaison with the relevant regulatory authorities;</p> <p>(5) setting up of special working group(s) to ensure compliance with the conditions of the Debt Securities (including but not limited to the use of proceeds, the meeting of the securities holders and the compliance with relevant rules and regulations); and</p> <p>(6) handling all other matters in connection with the issuance of the Debt Securities; and</p>			

SPECIAL RESOLUTION	No of votes (%)		Total number of votes present and voting
	FOR	AGAINST	
(iii) any one of the directors of the Company be authorised to take all such actions, do all such acts and things and execute all such further documents or deeds as he may, in his absolute discretion, consider necessary, appropriate, desirable or expedient for the purpose of, or in connection with, the implementation of or giving effect to any matters relating to the issuance of the Debt Securities as approved or confirmed by the board of the Company.”			

The holding of the Second EGM was in compliance with the requirements of the Company Law of the PRC and the Articles of Association of the Company. The Second EGM was chaired by Mr. Zhang Hua Wei, the chairman of the Company. As over two-thirds of the vote was casted in favour of the special resolution numbered (1) in the Second EGM, the resolution was duly passed by way of poll as an special resolution of the Company.

At the date of the Second EGM, the total number of Shares of the Company entitling the Shareholders to attend and vote for or against the resolution at the Second EGM was 4,522,332,324 H shares. There were no Shares entitling the holders to attend and vote only against the resolutions proposed at the Second EGM. Trustee who administers share award scheme of the Company did not exercise the voting rights attached to any of 23,564,000 Shares under the share award scheme.

威海朗普聯合會計師事務所有限公司 (Weihai Langpu Lianhe Accounting Company Limited)*, certified public accountants in the PRC and the auditor of the Company in the PRC, was appointed as the scrutineer for the vote-taking at the EGM and the Second EGM.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Zhang Hua Wei
Chairman

Weihai, Shandong, the PRC, 3 December 2020

As at the date hereof, the Board comprises of:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Long Jing (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)